92547-10-9

Upstream product

• 700-37-8 4-chloro-2-fluoro-nitrobenzene 
• 109-55-7 1-amino-3-(dimethylamino)propane 
• 611-06-3 2,4-dichloronitrobenzene 

Downstream Products

• 1616475-69-4 N³-(3-(dimethylamino)propyl)-4-nitro-N¹-(pyridin-3-yl)benzene-1,3-diamine 
• 1616475-72-9 N-(1-(3-(dimethylamino)propyl)-6-(pyridin-4-ylamino)-1H-benzo[d]imidazol-2-yl)benzamide 
• 1616475-71-8 N-(1-(3-(dimethylamino)propyl)-6-(pyridin-3-ylamino)-1H-benzo[d]imidazol-2-yl)benzamide 
• 1616475-68-3 N³-(3-(dimethylamino)propyl)-4-nitro-N¹-(pyridin-4-yl)benzene-1,3-diamine 
• 600725-16-4 4-chloro-N₂-(3-dimethylaminopropyl)-benzene-1,2-diamine 

Relevant academic research and scientific papers

Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site

We describe the exploration of N1-aryl-substituted benzimidazoles as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA. The design of the compounds was guided by the co-crystal structure of a benzimidazole viral translation inhibitor in complex with the RNA target. Structure-binding activity relationships of aryl-substituted benzimidazole ligands were established that were consistent with the crystal structure of the translation inhibitor complex.

Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site

We describe the exploration of N1-aryl-substituted benzimidazoles as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA. The design of the compounds was guided by the co-crystal structure of a benzimidazole viral translation inhibitor in complex with the RNA target. Structure-binding activity relationships of aryl-substituted benzimidazole ligands were established that were consistent with the crystal structure of the translation inhibitor complex.

Indole RSK inhibitors. Part 2: Optimization of cell potency and kinase selectivity

A series of inhibitors for the 90 kDa ribosomal S6 kinase (RSK) based on an 1-oxo-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]indole-8-carboxamide scaffold were optimized for cellular potency and kinase selectivity. This led to the identification of compound 24, BIX 02565, an attractive candidate for use in vitro and in vivo to explore the role of RSK as a target for the treatment heart failure.

10H-BENZO(G)PTERDINE-2,4-DIONE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

This invention pertains generally to the field of G-quadruplex ligands, and more particularly, to certain 10H-benzo[g]pteridine-2,4-dione compounds ("BPD compounds"), as described herein, which, inter alia, (selectively) bind (and stabilize) G-quadruplexes. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) bind (and stabilize) G-quadruplexes, to inhibit telomerase, to regulate cell proliferation, and in the treatment of proliferative disorders, such as cancer. Formula (I):

Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof

The present invention relates to substituted piperidines of general formula wherein R, R2 to R5, A, X, Z and n are defined as in claim 1, the tautomers, diastereomers, enantiomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.